Proven results
                Controlled mean Glycosylated Hemoglobin
                        The average estimated* glycosylated haemoglobin of users with regular use of SocialDiabetes is 6.7% for type 1 and 6.5% for type 2. 
                         
                    
                            Reduction of up to 1% of Glycosylated Hemoglobin in 3 months
                        
                            Users with type 1 diabetes with a high initial glycosylated haemoglobin (HbA1c > 8%), experience, on average, a reduction of 1% after 3 months of continuous use of SocialDiabetes. In the case of users with type 2 diabetes, this reduction rises to 2%.                        
                         
                    Join the largest community of users.
                
                    Thanks to SocialDiabetes our users ...                
                 
                        
                            Have eaten more than 7 million servings of carbohydrates.                        
                     
                        
                            More than 141 liters of rapid insulin have been put in.                        
                     
                        
                            Have taken more than 205,000 pills                         
                    Awards
                 
                        
                            Best mobile application in the health category - WSA United Nations                        
                     
                        
                            Best Health App 2015-2019 iSYS Foundation                        
                     
                        
                            Winners MunichRE InsurTech Accelerator 2016                        
                    Collaborators
                 
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                    
                    NextGenerationEU                
                
                        PROJECT: Towards a new generation of digital diabetes solutions: Artificial pancreas for patients with continuous monitoring devices and smart pen insulin. (2022 - 2025). Reference: CPP2021-008659. Funded by MCIN - 656.441,06€. P.I. Josep Vehí. Participants: SocialDiabetes, UdG                    
                     
                     
                    